In most industries, “better for you” is a marketing decision. In tobacco and nicotine, it is a regulated claim. Put “safer,” “less harmful,” or “reduced exposure” on a package, a website, or a sell sheet without the right federal order, and the bill rarely arrives as one fine. It arrives as packaging you throw away, inventory you cannot ship as labeled, campaigns you pull, and revenue that does not come in.
Here is where that line sits, what crossing it can cost, and the controls that prevent it.
When a marketing word becomes a regulated claim
Under federal law, a modified risk tobacco product is one sold or distributed for use to reduce harm or the risk of tobacco-related disease (FD&C Act §911(b)(1), 21 U.S.C. §387k(b)(1)). No one may introduce one into interstate commerce unless an FDA order is in effect for that product (21 U.S.C. §387k(a)).
What makes a product “modified risk” is mostly what is said about it. The statute reaches label, labeling, or advertising that explicitly or implicitly:
- Compares risk. The product is less harmful, or presents a lower risk of disease, than other tobacco products.
- Claims reduced exposure. It contains a reduced level of a substance, presents reduced exposure to one, or is free of one.
- Uses certain descriptors. “Light,” “mild,” “low,” or similar words.
(21 U.S.C. §387k(b)(2)(A).) It also reaches certain consumer-directed actions by a manufacturer outside the label and advertising, so the risk is not limited to what is printed on the box.
Some claims do not sound like health claims at first. FDA has treated an “additive free” package description as an unauthorized modified risk claim (FDA warning letter, 2015), and it has warned a company over statements made in outreach to consumers that its product was “much safer than cigarettes” (FDA, September 9, 2019).
A tobacco product in violation of the modified risk section is deemed adulterated (21 U.S.C. §387b(8)), and federal law sets civil money penalties for tobacco violations, with a higher tier for intentional violations of the modified risk prohibition (21 U.S.C. §333(f)(9)). How these rules apply to your products, and to marketing by retailers and distributors as well as manufacturers, is a question for your regulatory counsel, along with any state rules that add to them.
What an authorized claim looks like
Modified risk claims are not banned. They are earned, one product at a time. On June 30, 2026, FDA issued modified risk granted orders allowing 20 nicotine pouch products to be marketed with a specific claim: that using them instead of cigarettes puts the user at a lower risk of several named diseases (FDA, June 30, 2026). Those products already had marketing authorization from a separate FDA review in January 2025. The modified risk orders came from a second, separate review.
The details matter for anyone planning around a claim:
- Specific products. FDA states that an order refers to specific products, not an entire class. A similar product from another maker does not inherit the claim.
- Specific wording. The authorization covers a particular claim that compares those products to cigarettes. It is not a general license to say “safer.”
- A set term. These orders expire in five years unless renewed, and FDA may withdraw them, for example if youth use rises significantly.
- Ongoing obligations. The applicant must conduct postmarket surveillance and studies.
(FDA, June 30, 2026; 21 U.S.C. §387k(g) through (i).)
“FDA authorized” is not “FDA approved”
A separate rule bars any express or implied statement to consumers, in a label, labeling, media, or advertising, that a tobacco product is approved by FDA, deemed safe by FDA, endorsed by FDA, or safe or less harmful because FDA regulates or inspects it or because it meets FDA requirements (FD&C Act §301(tt), 21 U.S.C. §331(tt)).
Even an accurate mention of a marketing order needs careful wording, and the rule is written broadly, so retailers and distributors should ask counsel how it applies to their own signs, websites, and posts. For more on the difference between the two, see Authorized Doesn’t Mean Approved: Nicotine and the FDA.
What an unauthorized claim can cost
Legal exposure is for counsel to assess. The financial exposure lands in your books, and it is usually wider than owners expect:
- Relabeling and destroyed packaging. Printed cartons, labels, and inserts that carry the claim become scrap. Repacking stock already packed adds labor and new print runs.
- Inventory you cannot sell as labeled. Units with the claim may need to be held, reworked, or destroyed, and carrying costs continue while they sit.
- Marketing spend written off. Creative, prepaid media, displays, and influencer content built around the claim lose their value once pulled.
- Distributor and retailer chargebacks. Customers may charge back pull-and-replace costs, return product, or claw back promotional allowances under your agreements.
- Legal fees. Responding to a warning letter takes counsel’s time, often on short notice.
- Lost revenue. Shelf space and listings can slip away while corrected product works back into the channel.
Book and tax treatment can differ, and the gap matters most when the write-off is large. For financial statements, most inventory is measured at the lower of cost and net realizable value (ASC 330-10-35-1B). For tax, a loss generally needs more support: goods actually disposed of, or subnormal goods offered for sale at a reduced price within 30 days after the inventory date (Treas. Reg. §1.471-2(c)). Clean inventory accounting makes both computations easier to support.
A hypothetical: what one word can cost
Consider a hypothetical company that sells a private-label nicotine line, ships packaging that says “less harmful” without an order, and has to pull it:
- Packaging destroyed: 40,000 units at $0.25 each, or $10,000
- Repacking labor: 40,000 units at $0.15 each, or $6,000
- Marketing written off: $15,000 in creative and prepaid ads
- Retailer chargebacks: $8,000
- Regulatory counsel: $20,000
That is $59,000 before counting a single lost sale. Against a hypothetical $5,000 budgeted for counsel to review the packaging before it printed, skipping the review cost $54,000 more. Prevention is a budget line; the fix is a scramble.
Controls that keep a claim from shipping
The answer is not to stop marketing. It is to make the claims check as routine as the month-end close, one reason compliance can be an edge rather than a cost center.
- A claims review gate. Nothing ships, prints, or posts until every claim has been checked against an approved list and, where needed, signed off by regulatory counsel. That covers packaging, inserts, websites, social posts, emails, sell sheets, point-of-sale displays, and sales scripts. Record who approved what, and when.
- A budget for regulatory review. Give counsel’s review its own line in every launch budget and calendar, so it is not the first cost cut when a deadline slips. Then compare actual to budget like any other line.
- Claim status by SKU. Keep a register listing each SKU, every claim it carries, where the claim appears, the basis for it (including any FDA order and its expiration date), and who approved it.
- Packaging versions tied to inventory. Give each packaging version a code and track units on hand by version. If a claim has to come down, you can count what is affected in hours, not weeks.
- Contract terms you know. Know the compliance, chargeback, and indemnity terms in your distributor and retailer agreements, so a pull-and-replace cost is not a surprise.
- Expiration dates on the calendar. Authorized claims have a term. A claim that was valid at launch can lapse, and packaging in the warehouse does not update itself.
If a warning letter or a product pull does happen, talk with your accountant about whether related costs need to be accrued or disclosed in your financial statements (ASC 450-20).
How TreeStar can help
The TreeStar team can help tobacco and nicotine businesses build the financial side of claims control: bookkeeping and inventory accounting that tracks stock by SKU and packaging version, budgets that carry regulatory review as a real line item, financial modeling and cash flow planning for launches and pulls, and tax preparation and planning when write-offs hit. We provide regulatory accounting support alongside your counsel, who decides what you can say, through services like controller services and our tobacco and nicotine practice.
This article is general information, not advice for your situation. Rules change; confirm current law before acting.
